Zura Bio Ltd
ZURA4.350USD
+0.080+1.87%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
282.83MMarket Cap
LossP/E TTM
More Details of Zura Bio Ltd Company
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Zura Bio Ltd Info
Ticker SymbolZURA
Company nameZura Bio Ltd
IPO dateJul 16, 2021
CEODavis (Kim)
Number of employees30
Security typeOrdinary Share
Fiscal year-endJul 16
Address4225 Executive Square
CityLA JOLLA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92037
Phone18582470520
Websitehttps://zurabio.com/
Ticker SymbolZURA
IPO dateJul 16, 2021
CEODavis (Kim)
Company Executives of Zura Bio Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Someit Sidhu, M.D.
Dr. Someit Sidhu, M.D.
Director
Director
3.99M
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
652.39K
+62.13%
Dr. Kiran Nistala
Dr. Kiran Nistala
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
3.19K
--
Mr. Eric Hyllengren
Mr. Eric Hyllengren
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Dan Becker
Dr. Dan Becker
Independent Director
Independent Director
--
--
Dr. Neil Graham, M.D.
Dr. Neil Graham, M.D.
Independent Director
Independent Director
--
--
Mr. Gary Whale
Mr. Gary Whale
Chief Technology Officer
Chief Technology Officer
--
--
Ms. Kim Davis
Ms. Kim Davis
Interim Chief Executive Officer, Interim Principal Executive Officer, Chief Operating Officer, Chief Legal Officer and Corporate Secretary
Interim Chief Executive Officer, Interim Principal Executive Officer, Chief Operating Officer, Chief Legal Officer and Corporate Secretary
--
--
Ms. Jennifer Jarrett
Ms. Jennifer Jarrett
Independent Director
Independent Director
--
--
Mr. Sandeep Kulkarni, M.D.
Mr. Sandeep Kulkarni, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Someit Sidhu, M.D.
Dr. Someit Sidhu, M.D.
Director
Director
3.99M
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
652.39K
+62.13%
Dr. Kiran Nistala
Dr. Kiran Nistala
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
3.19K
--
Mr. Eric Hyllengren
Mr. Eric Hyllengren
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Dan Becker
Dr. Dan Becker
Independent Director
Independent Director
--
--
Dr. Neil Graham, M.D.
Dr. Neil Graham, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
8.42%
Hana Immunotherapeutics LLC
8.31%
VR Adviser, LLC
7.12%
J.P. Morgan Securities LLC
7.11%
Access Industries, Inc.
7.00%
Other
62.04%
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
8.42%
Hana Immunotherapeutics LLC
8.31%
VR Adviser, LLC
7.12%
J.P. Morgan Securities LLC
7.11%
Access Industries, Inc.
7.00%
Other
62.04%
Shareholder Types
Shareholders
Proportion
Hedge Fund
38.25%
Corporation
20.25%
Research Firm
7.96%
Individual Investor
7.49%
Venture Capital
7.12%
Investment Advisor/Hedge Fund
3.68%
Investment Advisor
3.57%
Other
11.68%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
171
33.26M
51.16%
-20.62M
2025Q2
175
61.14M
98.81%
-5.26M
2025Q1
176
62.77M
102.70%
-1.15M
2024Q4
196
61.97M
94.80%
-4.48M
2024Q3
181
65.04M
110.26%
-425.40K
2024Q2
164
62.71M
112.19%
-1.03M
2024Q1
154
45.76M
105.85%
-6.22M
2023Q4
146
45.65M
115.47%
+3.33M
2023Q3
134
44.62M
116.27%
+3.13M
2023Q2
116
43.65M
115.88%
+17.62M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Suvretta Capital Management, LLC
4.86M
7.48%
--
--
Jun 30, 2025
Hana Immunotherapeutics LLC
5.40M
8.31%
--
--
Apr 01, 2025
VR Adviser, LLC
4.63M
7.12%
-391.95K
-7.80%
Jun 30, 2025
J.P. Morgan Securities LLC
4.66M
7.16%
+2.08M
+80.44%
Jun 30, 2025
Access Industries, Inc.
4.55M
7%
+500.00K
+12.34%
May 21, 2025
Sidhu (Someit)
3.99M
6.14%
--
--
Apr 01, 2025
Great Point Partners, LLC
3.17M
4.88%
--
--
Jun 30, 2025
Pfizer Inc
2.97M
4.57%
--
--
Jun 30, 2025
Braidwell LP
2.47M
3.8%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Global X Russell 2000 ETF
0%
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
Global X Russell 2000 ETF
Proportion0%
Invesco Raymond James SB-1 Equity ETF
Proportion0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Zura Bio Ltd?
The top five shareholders of Zura Bio Ltd are:
Suvretta Capital Management, LLC holds 4.86M shares, accounting for 7.48% of the total shares.
Hana Immunotherapeutics LLC holds 5.40M shares, accounting for 8.31% of the total shares.
VR Adviser, LLC holds 4.63M shares, accounting for 7.12% of the total shares.
J.P. Morgan Securities LLC holds 4.66M shares, accounting for 7.16% of the total shares.
Access Industries, Inc. holds 4.55M shares, accounting for 7.00% of the total shares.
Suvretta Capital Management, LLC holds 4.86M shares, accounting for 7.48% of the total shares.
Hana Immunotherapeutics LLC holds 5.40M shares, accounting for 8.31% of the total shares.
VR Adviser, LLC holds 4.63M shares, accounting for 7.12% of the total shares.
J.P. Morgan Securities LLC holds 4.66M shares, accounting for 7.16% of the total shares.
Access Industries, Inc. holds 4.55M shares, accounting for 7.00% of the total shares.
What are the top three shareholder types of Zura Bio Ltd?
The top three shareholder types of Zura Bio Ltd are:
Suvretta Capital Management, LLC
Hana Immunotherapeutics LLC
VR Adviser, LLC
Suvretta Capital Management, LLC
Hana Immunotherapeutics LLC
VR Adviser, LLC
How many institutions hold shares of Zura Bio Ltd (ZURA)?
As of 2025Q3, 171 institutions hold shares of Zura Bio Ltd, with a combined market value of approximately 33.26M, accounting for 51.16% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -47.65%.
What is the biggest source of revenue for Zura Bio Ltd?
In --, the -- business generated the highest revenue for Zura Bio Ltd, amounting to -- and accounting for --% of total revenue.
